The EMI Scheme is funded by the Cambridge University Hospitals, NIHR Cambridge Biomedical Research Centre and Industry Partners. Prospective Pharmaceutical Industry companies who are interested to join in this strategic scheme should contact Prof Ian Wilkinson or Dr. Mellone Marchong in the first instance.
The PhD Studentships are fully funded posts which are 3 to 3.5 years depending on the experience of the candidate. The EMI scheme provides funds for the student’s stipend, university tuition & fees, and a standard amount towards training/travel. The scheme does not provide funding towards the PhD project; funding for the individual projects are to be sourced either by the academic or industry partner.
Academic Clinical Lecturer (ACL) posts are funded 50% by CUH and 50% by the EMI scheme. In this way, the ACL has the opportunity to spend 50% protected time on academic research with the remaining 50% in clinical training, during which time clinical competencies must be met. The ACL is funded for up to 4 years and all trainees must hold a PhD when appointed.
About the NIHR Cambridge BRC
The NIHR Cambridge BRC is a partnership between the CUH and the University of Cambridge. The NIHR provides substantial funding to the Cambridge BRC to translate fundamental biomedical research into clinical research that benefits patients. Part of this funding is distributed to Training and Academic Support for early career clinicians wishing to undertake biomedical research. The NIHR BRC has committed 1-year funds towards each studentship in the EMI Scheme.
Current EMI Industry Partners include AstraZeneca/MedImmune and GlaxoSmithKline:
About AstraZeneca and MedImmune
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory & Autoimmunity, Cardiovascular & Metabolic Disease and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com.
MedImmune is the global biologics research and development arm of AstraZeneca. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centers, with additional sites in Cambridge, UK and Mountain View, CA. For more information, please visit www.medimmune.com
AstraZeneca is constructing a new R&D centre and corporate headquarters at 1 Francis Crick Avenue, Cambridge Biomedical Campus; which will bring scientists from across both organisations together in one place in the UK.
AstraZeneca and MedImmune aim to support projects aligned to their main focus areas which are also of mutual interest to the EMI Scheme and academic partners.
GSK is a science-led, global healthcare company, committed to widening access to their products, so more people can benefit, no matter where they live or what they can afford. They employ approximately 16,000 people across 18 sites in the UK. In order to advance the training of bioscience skills and knowledge of the next generation of scientists, GSK and its Affiliates provide funding to the academic research base by supporting collaborations with academia for collaborative post-graduate research doctoral studentships and in this instance aim to support the University of Cambridge to train academic physician scientists in Experimental Medicine.